Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1754

1.

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.

Biologicals. 2019 Feb 9. pii: S1045-1056(18)30330-0. doi: 10.1016/j.biologicals.2019.01.007. [Epub ahead of print]

PMID:
30755369
2.

Fetal distress and urgent cesarean delivery due to new-onset peripartum Crohn's disease.

Rottenstreich M, Rottenstreich A, Rottenstreich M.

Taiwan J Obstet Gynecol. 2018 Dec;57(6):901-902. doi: 10.1016/j.tjog.2018.10.025. No abstract available.

3.

A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial.

Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, Valdivieso B, Correcher M, Aguas M.

J Med Internet Res. 2018 Nov 27;20(11):e11602. doi: 10.2196/11602.

4.
5.

A risk score system to timely manage treatment in Crohn's disease: a cohort study.

Pallotta N, Vincoli G, Pezzotti P, Giovannone M, Gigliozzi A, Badiali D, Vernia P, Corazziari ES.

BMC Gastroenterol. 2018 Nov 6;18(1):164. doi: 10.1186/s12876-018-0889-5.

6.

Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.

Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK.

Dig Dis Sci. 2019 Jan;64(1):60-67. doi: 10.1007/s10620-018-5322-y. Epub 2018 Oct 11.

PMID:
30311154
7.

Intra-abdominal Sepsis After Ileocolic Resection in Crohn's Disease: The Role of Combination Immunosuppression.

McKenna NP, Habermann EB, Glasgow AE, Dozois EJ, Lightner AL.

Dis Colon Rectum. 2018 Dec;61(12):1393-1402. doi: 10.1097/DCR.0000000000001153.

PMID:
30303885
8.

Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey.

Rodríguez-Lago I, Ferreiro-Iglesias R, Nos P, Gisbert JP; en representación del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).

Gastroenterol Hepatol. 2019 Feb;42(2):90-101. doi: 10.1016/j.gastrohep.2018.09.002. Epub 2018 Oct 4. English, Spanish.

PMID:
30293913
9.

Cerebral granulomatosis as a manifestation of Crohn's disease.

Whittaker K, Guggenberger K, Venhoff N, Doostkam S, Schaefer HE, Fritsch B.

BMC Neurol. 2018 Oct 3;18(1):161. doi: 10.1186/s12883-018-1163-8.

10.

Acute febrile neutrophilic dermatosis in a patient with Crohn's disease: case report and review of the literature.

Skok P, Skok K.

Acta Dermatovenerol Alp Pannonica Adriat. 2018 Sep;27(3):161-163. Review.

11.

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.

Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.

BMC Gastroenterol. 2018 Sep 15;18(1):140. doi: 10.1186/s12876-018-0868-x.

12.

Psychiatric comorbidities in patients with inflammatory bowel disease.

Bhamre R, Sawrav S, Adarkar S, Sakaria R, J Bhatia S.

Indian J Gastroenterol. 2018 Jul;37(4):307-312. doi: 10.1007/s12664-018-0870-9. Epub 2018 Sep 8.

PMID:
30196516
13.

Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.

Qian X, Wang T, Shen J, Ran Z.

Medicine (Baltimore). 2018 Aug;97(34):e11814. doi: 10.1097/MD.0000000000011814.

14.

Scalp psoriasis with increased hair density.

Shah VV, Lee EB, Reddy SP, Wu JJ.

Cutis. 2018 Jul;102(1):63-64.

PMID:
30138498
15.

Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.

Brady JE, Stott-Miller M, Mu G, Perera S.

Clin Ther. 2018 Sep;40(9):1509-1521.e5. doi: 10.1016/j.clinthera.2018.07.013. Epub 2018 Aug 17.

16.

Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.

Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.

PLoS One. 2018 Aug 16;13(8):e0201956. doi: 10.1371/journal.pone.0201956. eCollection 2018.

17.

Anti-TNF Therapy in Crohn's Disease.

Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P.

Int J Mol Sci. 2018 Jul 31;19(8). pii: E2244. doi: 10.3390/ijms19082244. Review.

18.

Risk factors for anastomotic recurrence after primary ileocaecal resection in Crohn's disease.

Aaltonen G, Keränen I, Carpelan-Holmström M, Lepistö A.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1143-1147. doi: 10.1097/MEG.0000000000001206.

PMID:
30024490
19.

Orofacial granulomatosis and erythema multiforme in an adolescent with Crohn's disease.

Georgesen C, Huang J, Avarbock A, Harp J, Magro C.

Pediatr Dermatol. 2018 Sep;35(5):e294-e297. doi: 10.1111/pde.13548. Epub 2018 Jun 26.

PMID:
30024055
20.

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1159-1167. doi: 10.1097/MEG.0000000000001197.

PMID:
29985208

Supplemental Content

Loading ...
Support Center